PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of California, San Diego
M.D. Anderson Cancer Center
Pfizer
Centre Antoine Lacassagne
BioAtla, Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Texas Southwestern Medical Center
University of California, San Diego
Gruppo Oncologico del Nord-Ovest
Washington University School of Medicine
Institute of Oncology Ljubljana
University of Arizona
University College, London
University of Cincinnati
The University of Texas Health Science Center at San Antonio
Stanford University
University of Cincinnati
National Cancer Institute, Naples
Eye & ENT Hospital of Fudan University
Pfizer
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
University of Wisconsin, Madison
University of Texas Southwestern Medical Center
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
UNC Lineberger Comprehensive Cancer Center
Odense University Hospital
University of Texas Southwestern Medical Center
UNC Lineberger Comprehensive Cancer Center
University of Chicago
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Chicago
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
University of Maryland, Baltimore
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Milton S. Hershey Medical Center
Daiichi Sankyo
Radiation Therapy Oncology Group
European Organisation for Research and Treatment of Cancer - EORTC
Eli Lilly and Company
Icahn School of Medicine at Mount Sinai
Azienda USL 4 Prato
University of California, Irvine
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)